Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study by Schuler, Martin, Prof, Cho, Byoung Chul, MD, Sayehli, Cyrus Michael, MD, Navarro, Alejandro, MD, Soo, Ross A, MBBS, Richly, Heike, MD, Cassier, Philippe Alexandre, MD, Tai, David, MBBS, Penel, Nicolas, MD, Nogova, Lucia, MD, Park, Se Hoon, MD, Schostak, Martin, MD, Gajate, Pablo, MD, Cathomas, Richard, MD, Rajagopalan, Prabhu, PhD, Grevel, Joachim, PhD, Bender, Sebastian, PhD, Boix, Oliver, PhD, Nogai, Hendrik, MD, Ocker, Matthias, MD, Ellinghaus, Peter, PhD, Joerger, Markus, MD

Get full text

Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study by Van Laethem, Jean-Luc, Prof, Borbath, Ivan, Prof, Prenen, Hans, Prof, Geboes, Karen Paula, Prof, Lambert, Aurélien, MD, Mitry, Emmanuel, MD, Cassier, Philippe Alexandre, MD, Blanc, Jean-Frédéric, Prof, Pilla, Lorenzo, MD, Batlle, Jaime Feliu, MD, Garrote, Mercedes Rodriguez, MD, Pazo-Cid, Roberto Antonio, MD, Gallego, Inmaculada, MD, Smith, Karin Enell, PhD, Ellmark, Peter, PhD, Pico de Coaña, Yago, PhD, Ambarkhane, Sumeet Vijay, MD, Macarulla, Teresa, MD

Get full text